The role of tumor markers in prognosing transitional bladder cancer;Utilidad de los marcadores tumorales en el pronóstico del cáncer transicional de vejiga

Actas Urologicas Espanolas

Volumn 27, Issue 7, 2003, Pages 501-512

  Lorenzo Gomez M F ^a,b   Schroeder, G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Department of Urology ^*  (United States)

Author keywords

Bladder; Marker prognosis; Tumor

Indexed keywords

CELL ADHESION MOLECULE; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; KI 67 ANTIGEN; METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; SCATTER FACTOR; TUMOR MARKER; VASCULOTROPIN;

BLADDER CANCER; CANCER GRADING; CHROMOSOME 17; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME ABERRATION; CYTOMETRY; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HUMAN; KARIOCYTOMETRY; MEDICAL LITERATURE; MEDLINE; OBSERVER VARIATION; ONCOGENE; ONCOGENE C ERB; ONCOGENE C ERBB2; ONCOGENE NEU; PROGNOSIS; PUBLICATION; REVIEW;

EID: 0041667970     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(03)72963-5     Document Type: Review

References (106)

1. BUSTO CATANON L, SÁNCHEZ MERINO JM, PICALLO SÁNCHEZ JA, GELABERT MAS A.: Clinical prognostic factors in superficial cancer of the urinary bladder. Arch Esp Urol 2001; 54 (2): 131-138.
2. MICHELI A, MARIOTTO A, GIORGI ROSSI A, GATTA G, MUTI P.: The prognostic role of gender in survival of adult cancer patients. Eur J Cancer 1998; 34 (14): 2271-2278.
3. IORI F, DE DOMINICIS C, LIBERTI M, FRIONI D, VAHEDI M, LEONARDO C, DE NUNZIO C, LAURENTI C.: Superficial bladder tumors in patients under 40 years of age: clinical, prognostic and cytogenetic aspects. Urol Int 2001; 67 (3): 224-227.
4. HARA S, MIYAKE H, FUJISAWA M, OKADA H, ARAKAWA S, KAMIDONO S, HARA I.: Prognostic variables in patients who have undergone radical cystectomy for transitional cell carcinoma of the bladder. Jpn J Clin Oncol 2001; 31 (8): 399-402.
5. JIMÉNEZ RE, GHEILER E, OSKANIAN P, TIGUERT R, SAKR W, WOOD DP JR, PONTES JE, GRIGNON DJ.: Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol 2000; 24 (7): 980-987.
6. WATTERS AD, BALLANTYNE SA, GOING JJ, GRIGOR KM, BARTLETT JM.: Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder. BJU Int 2000; 85 (1): 42-47.
7. BRODERS AC.: Epithelioma of the genitourinary organs. Ann Surg 1922; 75: 574.
8. EDWARD M, MESSING, CATALONA W.: Bladder cancer. Campbell's Urology. Seventh Edition 1998; 3: 2329-2410.
9. KOSHIKAVA T, LEYH H, SCHENCK U.: Difficulties in evaluating urinary specimens after local mitomycin therapy of bladder cancer. Diagn Cytopathol 1989; 5: 117.
10. TOSONI I, WAGNER U, SAUTER G, EGLOFF M, KNONAGEL H, ALUND G, BANNWART F, MIHATSCH MJ, GASSER TC, MAURER R.: Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 2000; 85 (1): 48-53.
11. MATOS T, CUFER T, CERVEK J, BORNSTNAR S, KRAGELJ B, ZUMER-PREGELJ M.: Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). Int J Radiat Oncol Biol Phys 2000; 46 (2): 403-409.
12. CHANG BS, KIM HL, YANG XJ, STEINBERG GD.: Correlation between biopsy and radical cystectomy in assessing grade and deph of invasion in bladder urothelial carcinoma. Urology 2001; 57 (6): 1063-1066.
13. BILLIS A, CARVALHO RB, MATTOS AC, NEGRETTI F, NOGUEIRA CR, OLIVEIRA MC, VALENCA JT JR, ADAM RL, COTTA AC, NUNES MS, DINAMARCO PV.: Tumor grade heterogeneity in urothelial bladder carcinoma: Proposal of a system using combined numbers. Scand J Urol Nephrol 2001; 35 (4): 275-279.
14. MILLÁN-RODRÍGUEZ F, CHECHILE-TONIOLO G, SALVADOR-BAYARRI J, PALOU J, VICENTE-RODRÍGUEZ J.: Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163 (1): 73-78.
15. SHARIAT SF, WEIZER AZ, GREEN A, LAUCIRICA R, FROLOV A, WHEELER TM, LERNER SP.: Prognostic value of p53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 2000; 56 (5): 735-740.
16. UCHIDA T, MINEI S, GAO JP, WANG C, SATOH T, BABA S.: Clinical significance of p53, MDM2, and bcl-2 expression in transitional cell carcinoma of the bladder. Oncol Rep 2002; 9 (2): 253-259.
17. WIJKSTROM H, EDSMYR F, LUNDH B.: The value of preoperative classification according to the TNM system. Eur Urol 1984; 10: 101.
18. YOUNES M, SUSSMAN J, TRUE L.: The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990; 66: 543.
19. PHILIP AT, AMIN MB, TAMBOLI P, LEE TJ, HILL CE, RO JY.: Intravesical adipose tissue: a quantitative study of its presence and location with implications for therapy and prognosis. Am J Surg Pathol 2000; 24 (9): 1286-1290.
20. HUGUET PÉREZ J, PALOU J, MILLAN RODRÍGUEZ F, VILLAVICENCIO MAVRICH H, RODRÍGUEZ JV.: Radical cystectomy for superficial tumors in the BCG era. Arch Esp Urol 2002; 55 (1): 50-56.
21. PANTAZOPOULOS D, IOAKIM-LIOSSI A, KARAKITSOS P, ARONI K, KAOLIRIS S, KANAVAROS P, KYRKON KA.: DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder. Anticancer Res 1997; 17 (1B): 781-786.
22. rd, FRIAS-HIDVEGI D, MCVARY K, BACUS JW.: Cytology, flow cytometry, image analysis and interphase cytogenetics by fluorescence in situ hibridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diag Cytopathol 1995; 13 (3): 214-223.
23. CIANCIULLI AM, BOVANI R, LEONARDO F, ANTENUCCI A, GANDOLFO GM, GIANNARELLI D, LEONARDO C, IORI F, LAURENTI C.: Interphase cytogenetics of bladder cancer progression: relationship between aneusomy, DNA ploidy pattern, histopathology and clinical outcome. Int J Clin Lab Res 2000; 30 (1): 5-11.
24. VAN RHIJN BW, VAN DER POEL HG, BOON ME, DEBRUYNE FM, SCHALKEN JA, WITJES JA.: Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high risk. Quanticyt 2000; 55 (3): 363-367.
25. OZER E, YORUKOGLU K, MUNGAN MU, OZKAL S, DEMIREL D, SAGOL O, KIRBA Z.: Prognostic significance of nuclear morphometry in superficial bladder cancer. Anal Quant Cytol Histol 2001; 23 (4): 251-256.
26. FUJIKAWA K, MATSUI Y, OKA H, FUKUZAWA S, SASAKI M, TAKEUCHI H.: The role of volume weighted mean nuclear volume in predicting the prognosis of patients with primary transitional cell carcinoma of the upper urinary tract: a report of 102 new cases. J Urol 2000; 164 (2): 352-355.
27. ÁLVAREZ KINDELAN J, LÓPEZ BELTRÁN A, REQUENA TAPIA MJ.: Biologia molecular en el cancer vesical. Actas Urol Esp 2000; 24 (8): 604-625.
28. WOLF HK, STOBER C, HOHENFELLNER R, LEISSNER J.: Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1G3 urothelial bladder carcinomas. Tumour Biol 2001; 22 (5): 328-336.
29. MORENO SIERRA J, LUENGO ALPUENTE S, LÓPEZ GARCÍA-ASENJO J, REDONDO GONZÁLEZ E, BLANCO JIMÉNEZ E, FERNÁNDEZ PÉREZ C, SILMI MOYANO A, RESEL ESTÉVEZ L.: Usefulness of p53 oncoprotein in urinary wash cytology: experience in patients with superficial bladder carcinoma. Arch Esp Urol 1999; 52 (9): 943-954.
30. MOYANO CALVO JL, DE MIGUEL RODRÍGUEZ M, POYATO GALÁN JM, ORTIZ GAMIZ A, MOLINA CARRANZA A, ZERPA RAILEY JJ, TORO CEPEDA H, SÁNCHEZ-BARRIGA PENA D, GALERA DAVIDSON H, CASTIÑEIRAS FERNÁNDEZ J.: DNA ploidy determination with flow cytometry, Ki-index and overexpression of p53 protein in 121 T1 superficial bladder carcinomas. Retrospective studies. Part II: Prognostic value and usefulness in the indication for prophylactic treatment with BCG. Actas Urol Esp 2001; 25 (1): 32-45.
31. TOKTAS G, TURKERI LN, UNLUER E, ATUG F, MURAT C, OZVEREN B, CALISKAN M, AKDAS A.: Prognostic significance of p53 protein accumulation in stage pT1 transitional cell carcinoma of the bladder. Int Urol Nephrol 1999; 31 (4): 437-441.
32. GAO JP, UCHIDA T, WANG C, JIANG SX, MATSUMOTO K, SATOH T, MINEI S, SOH S, KAMEYA T, BABA S.: Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Int J Oncol 2000; 16 (3): 469-475.
33. MORENO SIERRA J, LÓPEZ GARCÍA ASENJO JA, REDONDO GONZÁLEZ E, FERNÁNDEZ PÉREZ C, MAESTRO DE LAS CASAS ML, BLANCO JIMÉNEZ E, SILMI MOYANO A, RESEL ESTÉVEZ L.: Usefulness of p53 oncoprotein immunohistochemistry in the follow up of bladder carcinoma: a 5 year study. Arch Esp Urol 1999; 52 (8): 840-848.
34. LEISSNER J, HOHENFELLNER R, THUROFF JW, KOPPEN C, WOLF HK.: Prognostic significance of histopathological grading and immunoreactivity for p53 and p21/WAF1 in grade 2 pTa transitional cell carcinoma of the urinary bladder. Eur Urol 2001; 39 (4): 438-445.
35. KRUSPSKI T, MOSKALUK C, BOYD JC, THEODORESCU D.: A prospectivepilot evaluation of urinary and immunohistochemiacl markers as predictors of clinical stage of urothelial carcinoma of the bladder. BJU Int 2000; 85 (9): 1027-1032.
36. GONTERO P, CASETTA G, ZITELLA A, BALLARIO R, PACCHIONI D, MAGNANI C, MUIR GH, TIZZANI A.: Evaluation of p53 protein overexpression, Ki-67 proliferative activity and mitotic index as markers of tumor recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000; 38 (3): 287-296.
37. FRIEDRICH MG, RIETHDORF S, ERBERSDOBLER A, TIEMER C, SCHWAIBOLD H, SOLTER JK, HULAND E, RIETHDORF L, CONRAD S, HAMMERER PG, HULAND H.: Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. Eur Urol 2001; 39 (2): 159-166.
38. SCHMITZ-DRAGER BJ, GOEBELL PJ, EBERT T, FRADET Y.: p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000; 38 (6): 691-699.
39. BERNARDINI S, CHABANNES E, BITTARD H.: Usefulness of p53 in the clinical management of bladder tumors. Prog Urol 2001; 11 (2): 201-208.
40. ASCI R, YILDIZ L, SARIKAYA S, BUYUKALPELLI R, YILMAZ AF, KANDEMIR B.: p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder. Urol Int 2001; 67 (1): 34-40.
41. LENG J, ZHANG Y, YAO X.: Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder. Zhonghua Wai Ke Za Zhi 2000; 38 (1): 40-43.
42. MIYAMOTO H, KUBOTA Y, NOGUCHI S, TAKASE K, MATSUZAKI J, MORIYAMA M, TAKEBAYASHI S, KITAMURA H, HOSAKA M.: c-erbB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 2000; 55 (5): 679-683.
43. MORENO SIERRA J, MAESTRO DE LAS CASAS ML, REDONDO GONZÁLEZ E, FERNÁNDEZ PÉREZ C, DEL BARCO BARRIUSO V, SANZ CASLA MT, BLANCO JIMÉNEZ E, SILMI MOYANO A, RESEL ESTÉVEZ L.: p185 (Neu) oncoprotein in the prognosis on bladder carcinoma. Experience of 5 years. Arch Esp Urol 2000; 53 (3): 238-244.
44. JIMÉNEZ RE, HUSSAIN M, BIANCO FJ JR, VAISHAMPAYAN U, TABAZCKA P, SAKR WA, PONTES JE, WOOD DP JR, GRIGNON DJ.: Her-2/neu overexpression in muscle invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7 (8): 2440-2447.
45. SIMONEAU M, LA RUE H, ABOULKASSIM TO, MEYER F, MOORE L, FRADET Y.: Chromosome 9 deletions and recurrence of superficial bladder cancer: Identification of four regions of prognostic interest. Oncogene 2000; 19 (54): 6317-6323.
46. EDWARDS J, DUNCAN P, GOING JJ, GRIGOR KM, WATTERS AD, BARTLETT JM.: Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder. Br J Cancer 2001; 85 (12): 1894-1899.
47. EDWARDS J, DUNCAN P, GOING JJ, WATTERS AD, GRIGOR KM, BARTLETT JM.: Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol 2002; 196 (4): 380-385.
48. OOSTERHUIS JW, SCHAPERS RF, JANSSEN-HEIJNEN ML, SMEETS AW, PAUWELS RP.: MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 2000; 88 (11): 2598-2605.
49. WU TT, CHEN JH, LEE YH, HUANG JK.: The role of bcl-2, p53, and Ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000; 163 (3): 758-760.
50. SGAMBATO A, MIGALDI M, FARAGLIA B, DE ALOYSIO G, FERRARI P, ARDITO R, DE GAETANI C, CAPELLI G, CITTADINI A, TRENTINI GP.: Cyclin D1 expression in papillary superficial bladder cancer: Its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 2002; 97 (5): 671-678.
51. KORKOLOPOULOU P, CHRISTODOULOU P, KONSTANTINIDOU AE, THOMAS-TSAGLI E, KAPRALOS P, DAVARIS P.: Cell cycle regulators in bladder cancer: A multivariate survival study with emphasis on p27Kip1. Hum Pathol 2000; 31 (6): 751-760.
52. CHOW NH, TZAI TS, CHENG HL, LIU HS, CHAN SH, TONG YC.: The clinical value of p21WAF1/CIP1 expression in superficial bladder cancer. Anticancer Res 2000; 20 (2B): 1173-1176.
53. MIGALDI M, SGAMBATO A, GARAGNANI L, ARDITO R, FERRARI P, DE GAETANI C, CITTADINI A, TRENTINI GP.: Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 2000; 6 (8): 3131-3138.
54. KORKOLOPOULOU P, KONSTANTINIDOU AE, THOMAS-TSAGLI E, CHRISTODOULOU P KAPRALOS P, DAVARIS P.: Waf1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer. Immunohistochem 2000; 8 (4): 285-292.
55. KAMAI T, TAKAGI K, ASAMI H, ITO Y, OSHIMA H, YOSHIDA KI.: Decreasing of p27 (Kip1) and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001; 84 (9): 1242-1251.
56. TAKAGI Y, TAKASHI M, KOSHIKAWA T, SAKATA T, OHSHIMA S.: Immunohistochemical demosnstration of cyclin D 1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol 2000; 7 (10): 366-372.
57. TOMOBE M, SHIMAZUI T, UCHIDA K, AKAZA H.: AgNOR count in resting cells (resting NOR) is a new prognostic marker in invasive bladder tumor. Anal Cell Pathol 2001; 22 (4): 193-199.
58. BOZLU M, ORHAN D, BALTACI S, YAMAN O, ELHAN AH, TULUNAY O, MUFTUOGLU YZ.: The prognostic value of proliferating cell nuclear antigen, Ki-67 and nucleolar organizer region in transitional cell carcinoma of the bladder. Int Urol Nephrol 2002; 33 (1): 59-66.
59. WANG S, XIA T, ZHANG Z.: Expression of VEGF and tumor angiogenesis in bladder cancer. Zhonghua Wai Ke Za Zhi 2000; 38 (1): 34-36.
60. BERNARDINI S, FAUCONNET S, CHABANNES E, HENRY PC, ADESSI G, BITTARD H.: Serum Levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001; 166 (4): 1275-1279.
61. CHOW NH, LIU HS, CHAN SH, CHENG HL, TZAI TS.: Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res 1999; 19 (5C): 4593-4597.
62. CREW JP, FUGGLE S, BICKNELL R, CRANSTON DW, DE BENEDETTI A, HARRIS AL.: Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000; 82 (1): 161-166.
63. CHAUDHARY R, BROMLEY M, CLARKE NW, BETTS CD, BARNARD RJ, RYDER WD, KUMAR S.: Prognostic relevance of microvessel density in cancer of the urinary bladder. Anticancer Res 1999; 19 (4C): 3479-3484.
64. KORKOLOPOULOU P, KONSTANTINIDOU AE, KAVANTZAS N, PATSOURIS E, PAVLOPOULOS PM, CHRISTODOULOU P, THOMAS-TSAGLI E, DAVARIS P.: Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer. Virchows Arch 2001; 438 (6): 603-611.
65. SAGOL O, YORUKOGLU K, SIS B, TUNA B, OZER E, GURAY M, MUNGAN U, KIRKALI Z.: Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder? Urology 2001; 57 (5): 895-899.
66. CHABANNES E, BERNARDINI S, WALLARAND H, BITTARD H.: Angiogenesis in bladder: prognosis indicator and therapeutic target. Prog Urol 2001; 11 (3): 417-427.
67. VAN RHIJN BW, LURKIN I, RADVANYI F, KIRKELS WJ, VAN DER KWAST TH, ZWARTHOFF EC.: The fibroblastic growth factor receptor 3(FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61 (4): 1265-1268.
68. MORENO SIERRA J, MAESTRO DE LAS CASAS ML, REDONDO GONZÁLEZ E, FERNÁNDEZ PÉREZ C, DEL BARCO BARRIUSO V, SANZ CASLA MT, BLANCO JIMÉNEZ E, SILMI MOYANO A, RESEL ESTÉVEZ L.: Epidermal growth factor receptor (EGFR) in the prognosis of bladder carcinoma. Experience of 5 years. Arch Esp Urol 2000; 53 (4): 323-331.
69. THOGERSEN VB, SORENSEN BS, POULSEN SS, ORNTOFT TF, WOLF H, NEXO E.: A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001; 61 (16): 6227-6233.
70. GOHJI K, NOMI M, NIITANI Y, KITAZAWA S, FUJII A, KATSUOKA Y, NAKAJIMA M.: Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J Clin Oncol 2000; 18 (16): 2963-2971.
71. ARIMA J, IMAZONO Y, TAKEBAYASHI Y, NISHIYAMA K, SHIRAHAMA T, AKIBA S, FURUKAWA T, AKIYAMA S, OHI Y.: Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 2000; 88 (5): 1131-1138.
72. SEDDIGHZADEH M, STEINECK G, JANSSON O, LARSSON P, WIJKSTROM H, ADOLFSSON J, PORTWOOD N, HANSSON J, LINDER S.: Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma. Br J Cancer 2001; 84 (3): 329-334.
73. ANDREWS B, SHARIAT SF, KIM JH, WHEELER TM, SLAWIN KM, LERNER SP.: Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 2002; 167 (3): 1475-1481.
74. BYRNE RR, SHARIAT SF, BROWN R, KATTAN MW, MORTON RA JR, WHEELER TM, LERNER SP.: E-Cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term follow-up. J Urol 2001; 165 (5): 1473-1479.
75. NAKOPOULOU L, ZERVAS A, GAKIOPOULOU-GIVALOU H, CONSTANTINIDES C, DOUMANIS G, DAVARIS P, DIMOPOULOS C.: Prognostic value of E-cadherin, beta-catenin, P120ctn in patients with transitional cell bladder cancer. Anticancer Res 2000; 20 (6B): 4571-4578.
76. GARCÍA DEL MURO X, TORREGOSA A, MUÑOZ J, CASTELLSAGUE X, CONDOM E, VIGUES F, ARANCE A, FABRA A, GERMA JR.: Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. Eur J Cancer 2000; 36 (3): 357-362.
77. SHARIAT SF, PAHLAVAN S, BASEMAN AG, BROWN RM, GREEN AE, WHEELER TM, LERNER SP.: E-catherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 2001; 57 (1): 60-65.
78. MIYAKE H, ETO H, ARAKAWA S, KAMIDONO S, HARA I.: Over expression of CD44v8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J Urol 2002; 167 (3): 1282-1287.
79. TOMA V, HAURI D, SCHMID U, ACKERMANN D, MAURER R, ALUND G, KNONAGEL H, RIST M, GASSER TC, SAUTER G, ROTH J.: Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol 1999; 155 (5): 1427-1432.
80. MIZUTANI Y, HONGO F, SATO N, OGAWA O, YOSHIDA O, MIKI T.: Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 2001; 92 (2): 287-293.
81. HARA I, MIYAKE H, HARA S, ARAKAWA S, KAMIDONO S.: Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J Urol 2001; 165 (5): 1769-1772.
82. NAKOPOULOU L, GAKIOPOULOU H, ZERVAS A, GIANNOPOULOU I, CONSTANTINIDES C, LAZARIS AC, LIAPIS H, KYRIAKOU G, DIMOPOULOS C.: MMP-3mRNA and MMP-3 and MMP-1 proteins in bladder cancer: A comparison with clinicopathologic features and survival. Appl Immunohistochem Mol Morphol 2001; 9 (2): 130-137.
83. MIYAKE H, GLEAVE M, KAMIDONO S, HARA I.: Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002; 59 (1): 150-154.
84. SHIRAHAMA T, ARIMA J, AKIBA S, SAKAKURA C.: Relation between cyclooxigenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92 (1): 188-193.
85. YAMANAKA M, KANDA K, LI NC, FUKUMORI T, OKA N, KANAYAMA HO, KAGAWA S.: Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001; 166 (6): 2495-2499.
86. HANADA T, NAKAGAWA M, EMOTO A, NOMURA T, NASU N, NOMURA Y.: Prognostic value of tumor-associated macrophage count in human bladder. Int J Urol 2000; 7 (7): 263-269.
87. NAKOPOULOU L, ZERVAS A, LAZARIS AC, CONSTANTINIDES C, STRAVODIMOS C, DAVARIS P, DIMOPOULOS C.: Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinoma. J Clin Pathol 2001; 54 (4): 309-313.
88. PATARD J, MOUDOUNI S, SAINT F, RIOUX-LECLERCQ N, MANUNTA A, GUY L, BALLANGER P, LANSON Y, HAJRI M, IRANI J, GUILLE F, BEURTON D, LOBEL B, BERNAR LOBEL and The members of the Groupe Necker.: Tumor progression and survival in patients with T1G3 bladder tumors: Multicentric retrospective study comparing 94 patients treated during 17 years. Urology 2001; 58 (4): 551-556.
89. SOLSONA E, IBORRA I, DUMONT R, RUBIO-BRIONES J, CASANOVA J, ALMENAR S.: The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000; 164 (3Pt1): 690-691.
90. HERR HW, SOGANI PC.: Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001; 166 (4): 1296-1299.
91. TAKASHI M, WAKAI K, HATTORI T, FURUHASHI K, ONO Y, OHSHIMA S, OHNO Y.: Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (ToKyo 172 strain) therapy: Significance of concomitant carcinoma in situ. Int Urol Nephrol 2002; 33 (1): 41-47.
92. SAINT F, PATARD JJ, MAILLE P, SOYEUX P, HOZNEK A, SALOMON L, ABBOU CC, CHOPIN DK.: Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 2002; 167 (1): 364-367.
93. LEBRET T, BECETTE V, HERVE JM, MOLINIE V, BARRE P, LUGAGNE PM, GENTILLE A, BAGLIN AC, BOTTO H.: Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high risk selected population of patients with stage T1 grade G3 bladder cancer.
94. BLANCHET P, DROUPY S, ESCHWEGE P, VIELLEFOND A, PARADIS V, PICHON MF, JARDIN A, BENOIT G.: Prospective evaluation of Ki-67 labeling in predicting the recurrence and progression of superficial bladder transitional cell carcinoma. Eur Urol 2001; 40 (2): 169-175.
95. THALMANN GN, SERMIER A, RENTSCH C, MOHRLE K, CECCHINI MG, STUDER UE.: Urinary Interleukin 8 and 18 predict the response of superficial bladder cancer to intravesical therapy with Bacillus Calmette-Guerin. J Urol 2000; 164 (6): 2129-2133.
96. DE VERE WHITE RW, DEITCH AD, DANESHMAND S, BLUMENSTEIN B, LOWE BA, SAGALOWSKY AI, SMITH JA JR, SCHELLHAMMER PF, STANISIC TH, GROSSMAN HB, MESSING E, CRISSMAN JD, CRAWFORD ED.: The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study. Eur Urol 2000; 37 (5): 595-600.
97. GSCHWEND JE, DAHM P, FAIR WR .: Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur Urol 2002; 41 (4): 440-448.
98. SLOJEWSKI M: Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion. Ann Acad Med Stetin 2000; 46: 217-229.
99. LEISSNER J, ALLHOFF EP, HOHENFELLNER R, WOLF HK.: Significance of pelvic lymphadenectomy for the prognosis after radical cystectomy. Zentralbl Chir 2002; 127 (4): 315-321.
100. ONG F, MOONEN LM, GALLEE MP, TEN BOSCH C, ZERP SF, HART AA, BARTELINK H, VERHEIJ M.: Prognostic factors in transitional cell cancer of the bladder: an emerging role of Bcl-2 and p53. Radiother Oncol 2001; 61 (2): 169-175.
101. RODEL C, GRABENBAUER GG, RODEL F, BIRKENHAKE S, KUHN R, MARTUS P, ZORCHER T, FURSICH D, PAPADOPOULOS T, DUNST J, SCHROTT KM, SAUER R: Apoptosis, p53, bcl-2 and Ki-67 in invasive bladder carcinoma: Possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000; 46 (5): 1213-1221.
102. KOGA F, KITAHARA S, ARAI K, HONDA M, SUMI S, YOSHIDA K.: Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer. Jpn J Cancer Res 2000; 91 (4): 416-423.
103. INOUE K, SLATON JW, KARASHIMA T, YOSHIKAWA C, SHUIN T, SWEENEY P, MILLIKAN R, DINNEY CP.: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000; 6 (12): 4866-4873.
104. SOYGUR T, BEDUK Y, BALTACI S, YAMAN O, TOKGOZ G.: The prognostic value of peripheral blood lymphocyte subsets in patients with bladder carcinoma treated using neoadjuvant M-VEC chemotherapy. BJU Int 1999; 84 (9): 1069-1072.
105. MIZUTANI Y, WADA H, OGAWA O, YOSHIDA O, FUKUSHIMA M, NONOMURA N, MIKI T.: Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 2001; 92 (3): 510-518.
106. MARBERGER M, STOECKLE M, PASANDORO V, STERNBERG CN.: Management and outcome in invasive and locally advanced bladder cancer. Eur Urol 2001; 40/5 (Curric Urol 1-9).